AscellaHealth, a leading global partner in customisable solutions for the specialty pharmaceutical industry, has announced its role as Gold Sponsor of the upcoming World Orphan Drug Congress Europe (WODC). The event is scheduled to take place from 22nd to 25th October 2024 in Barcelona, Spain.
The WODC is renowned as the largest and most established conference dedicated to orphan drugs and rare diseases worldwide. This annual gathering brings together industry leaders, healthcare professionals, and stakeholders to discuss advancements in orphan drug development and strategies for enhancing patient access to therapies. AscellaHealth will showcase its comprehensive suite of end-to-end solutions, designed to streamline the commercialisation process for life science manufacturers globally. These solutions are aligned with the WODC’s mission to improve clinical outcomes for patients suffering from complex, chronic conditions and rare diseases.
Gillian Molloy, Vice President of Market Access at AscellaHealth, is set to present at the conference on 23rd October at 16:40 in Theatre 6. Her presentation, titled “Leading the Way: Streamlining Commercialisation of Rare Disease Therapies, Supporting Access, and Improving Patient Outcomes,” will delve into innovative approaches for optimising the treatment journey for patients with rare diseases.
Additionally, AscellaHealth will host a Pre-conference Networking Event on 22nd October from 16:30 to 18:00 at the Plaza Catalonia Hotel. This event aims to connect global leaders in the life sciences industry and foster collaboration among participants.
Conference attendees are encouraged to visit AscellaHealth’s Exhibition Booth #29, where they can meet with a team of global experts. These professionals will discuss innovative commercialisation solutions that enhance and extend the capabilities of manufacturers’ in-house teams, providing insight into the complex landscape of specialty pharmaceuticals.
Molloy highlighted the company’s commitment to improving the quality of life for patients and families through customised, patient-centric programmes that optimise treatment journeys. “At AscellaHealth, we serve as a trusted, single-source partner for specialty drug manufacturers, providing an integrated approach to pre-commercialisation, product launch, market access, and exclusive product distribution,” she stated. “Our commitment includes supporting healthcare providers and patients with rare disease management and therapy administration, along with negotiating pricing and reimbursement with both government and private payers.”
AscellaHealth’s participation in the WODC reflects its ongoing dedication to advancing orphan drug development and improving patient access to essential therapies. The company aims to expand its partner portfolio and leverage its expertise to effectively manage the growth of emerging therapies and next-generation technologies throughout the specialty pharmacy value chain.
The World Orphan Drug Congress Europe presents a vital platform for industry stakeholders to discuss pressing issues and collaborative efforts in the rare disease landscape. AscellaHealth’s presence as a Gold Sponsor underscores its pivotal role in shaping the future of specialty pharmaceuticals and enhancing patient outcomes in the realm of rare diseases. Visit www.AscellaHealth.eu